

Dyspnea in Dying Patients

DAVID H.S. HSU, MSC, MD

SUMMARY

Dyspnea is common in terminally ill patients and is often fairly difficult to control. If specific causes cannot be identified or treated, general measures to relieve symptoms should be used. Nondrug measures (eg, discussion and explanation with the patient) and drug measures (eg, morphine) can be used to control the dyspnea, although side effects, such as sedation, can be problematic.

RÉSUMÉ

La dyspnée est un phénomène courant chez les patients en phase terminale et elle est souvent difficile à contrôler. Lorsqu'il s'avère impossible d'identifier ou de traiter l'étiologie spécifique, on devrait prévoir des mesures générales visant à soulager les symptômes. Les mesures non pharmacologiques (p. ex. explication et discussion avec le patient) et médicamenteuses (p. ex. morphine) peuvent être utiles pour contrôler la dyspnée bien que certains effets indésirables, telle la sédation, peuvent devenir problématiques.

Can Fam Physician 1993;39:1635-1638.

DYSPNEA IS A PATIENT'S SUBJECTIVE awareness of difficulty in breathing. It can be described as laboured breathing, tightness, air hunger, sensation of suffocation, or breathlessness. The patient is anxious and in severe cases has a sense of impending death. Physical signs, such as tachypnea, hyperpnea, and use of accessory muscles of respiration are usually associated with dyspnea, but occasionally signs of increased ventilatory effort do not result in significant dyspnea (eg, metabolic acidosis). Dyspnea in patients with terminal illness, in a palliative care setting, is often referred to as "terminal dyspnea."

Because no objective method of measuring dyspnea exists, the reported incidence in terminal patients varies. Very generally speaking, about 50% (up to 70% in one study) of patients with terminal cancer demonstrate dyspnea, and of those with lung cancer, about 70% have dyspnea.³ The higher incidence of dyspnea in lung cancer patients is consistently noted in fairly large studies. One study of 381 patients found that 69% of lung cancer patients showed signs of dyspnea.⁵ The

Dr Hsu practises family medicine at the Seymour Medical Clinic with a special interest in palliative care and is a consultant in palliative care at University Hospital, Shaughnessy Site, in Vancouver.

National Hospice Study found 65% of lung cancer patients had dyspnea.³ Although one would expect dyspnea in patients with lung cancer, almost 25% of patients with terminal illness have dyspnea unrelated to lung cancer or concurrent respiratory or cardiac disease.³ General debility or other medical problems must also be considered.

Dyspnea tends to increase as patients approach death: eg, the incidence increased from 17% of patients at 4 weeks before death to 28% during the last week.⁶ During the last week of life, 25% to 30% of patients have dyspnea as a significantly distressing symptom.^{2,3,6} Unfortunately, dyspnea seems fairly difficult to control, often more difficult to control than pain. Dyspnea was the most common symptom uncontrollable without sedating the patient in one study.⁷ And dyspnea has been referred to as "the most common severe main symptom" at death.²

Pathophysiology

Dyspnea can be caused by increased ventilatory demand (fever, anxiety, anemia); decreased ventilatory capacity (obstruction, lung stiffness, loss of normal lung tissue, respiratory muscle dysfunction); or neural stimulation (intracranial pressure, stroke, tumour).⁵ These processes act through stimulation of the brainstem respiratory centres by central and peripheral

chemoreceptors sensitive to increased PCO_2 , decreased PO_2 , or decreased pH levels; by peripheral neuroreceptors; or by cortical or thalamic effects.⁴

However, the degree of dyspnea is not necessarily related directly to the degree of stimulation of such receptors. Some suggest that the sensation of dyspnea or breathlessness depends on the perception of the degree of respiratory muscle effort, ie, efferent motor command signals.⁸ Thus, if both intercostal muscles and diaphragm are paralyzed, there might not be a perception of dyspnea. Other theories have also been postulated.⁹ As with pain and other symptoms, dyspnea has an affective or psychological component. It clearly is increased by depression, anxiety, etc.

Dyspnea in palliative care can be thought of as due to 1) known existing conditions (eg, chronic obstructive pulmonary disease, asthma, congestive heart failure, anemia); 2) an acute superimposed condition, usually of the respiratory system (eg, atelectasis, pulmonary embolus, pneumonia, acidosis); 3) directly as a result of the cancer (eg, obstruction of bronchus, replacement of normal lung tissue, lymphangitis carcinomatosa, phrenic nerve involvement, superior vena cava obstruction, pleural effusion, ascites); or 4) secondary to cancer therapy (eg, radiation fibrosis, pneumothorax, chemotherapy).^{3,4} More often than not, several different factors contribute to a patient's dyspnea.

Management

If a specific cause of dyspnea can be identified, the usual treatments can be instituted, eg, bronchodilators for chronic obstructive pulmonary disease, diuretics for congestive heart failure, radiotherapy for tumour, transfusion for severe anemia. In palliative care one must also consider the appropriateness of investigations and treatment. For example, antibiotic treatment of pneumonia might or might not be consistent with the patient's wishes for treatment.

If a specific cause is not identified or treatable, then measures to relieve the symptoms of dyspnea should be considered. General measures include taking time to talk to the patient and explaining the problem and plans for symptom con-

trol and treatments. A cool draft from a fan or window is often helpful. Increased humidity can be beneficial. Breathing exercises, physical therapy, and postural drainage can be considered, although sometimes they are impractical because of the general condition of the patient. Reducing the physical exertions required of the patient is often fairly simple if explicitly reviewed. Expectorants or mucolytic agents (eg, nebulized acetylcysteine) are useful in selected cases.^{4,10}

Opioids, usually morphine, can be used to control dyspnea in dying patients. Since the 19th century, opiates have been used to relieve symptoms of asthma, pneumothorax, and emphysema.¹¹ Morphine reduces the subjective sense of dyspnea. It reduces the respiratory centre response to stimulation by increased PCO_2 or decreased PO_2 , and respiratory rate decreases after morphine administration.⁵ However, a decrease in ventilatory function might not be evidenced by blood gas levels. Studies have shown that opiates given to patients with chronic obstructive pulmonary disease resulted in decreased breathlessness, increased exercise tolerance, and no significant deterioration of blood gas levels.¹⁰ Morphine relieves dyspnea without much change in respiratory rate or blood gas measurements.¹² It appears that oxygen consumption is decreased by morphine, perhaps by reducing anxiety, muscle tension, and restlessness.

Conversely, patients with relatively normal blood gas levels can have severe dyspnea (eg, in lymphangitis carcinomatosa), where morphine seems simply to "reset" the level of respiratory drive.⁵ The increased respiratory rate and effort associated with dyspnea can be counterproductive (eg, increased dead space ventilation and decreased alveolar ventilation), so that the effect of morphine, reducing respiratory rate, can in these instances actually improve ventilatory function.⁴

Morphine should be taken by mouth if possible. If a patient is already receiving morphine for pain, the dosage is increased by 50%. If a patient is not already receiving morphine or another opioid, then morphine, 5 mg every 4 hours, can be started. Further titration of dosage is

based on response and degree of side effects. For example, the dosage can be increased to 10 mg every 4 hours the next day, and then to 15 to 20 mg every 4 hours if dyspnea persists (respiratory rate greater than 24 respirations/min can be used as a guide).⁴ A similar, slightly more detailed, protocol aims to control dyspnea and uses as a respiratory rate guideline for maintenance 12 to 15 respirations/min.¹³

If oral morphine is not tolerated, subcutaneous morphine can be used with good response.¹² In more severe cases, an intravenous infusion can be used. One approach uses a 1- to 2-mg bolus every 5 to 10 minutes until the dyspnea is relieved. Then the infusion is maintained at an hourly rate at 50% of the cumulative bolus amount.¹⁴ The dosage can be increased 25% every 24 hours, subject to side effects of the morphine, notably sedation. It seems better to use an additional bolus as needed for exacerbations of dyspnea, rather than increasing the infusion rate, unless there are many exacerbations within a 24-hour period.

If the infusion does cause sedation, it should be stopped until recovery and then restarted at 50% of the previous rate. Naloxone should be used very cautiously to reverse sedation, as it appears to result in acute return of dyspnea.

Other medications can also be used to provide symptomatic relief of terminal dyspnea. Diazepam, or similar anxiolytics, can be useful if anxiety is a large component of the dyspnea.⁴ However, diazepam has been noted to increase breathlessness and reduce exercise tolerance in patients with airway obstruction.¹⁵ Promethazine has been tried with some relief of dyspnea. Oxygen can be used, preferably by nasal prongs or light mask, but the benefits must be weighed against the inconvenience of the apparatus for the patient. Nebulized bupivacaine has been mentioned, directed at the J-receptors, and could be useful for lymphangitis carcinomatosa. Glucocorticoids are useful in some instances, eg, bronchospasm, edema, lymphangitis carcinomatosa, laryngeal stricture, superior vena cava syndrome.⁵ Prednisone, 20 to 40 mg/day, or dexamethasone, 2 to 4 mg twice daily, can be used. At the terminal stage, atropine, 0.4 to 1.0 mg every 4 to 8 hours, can be used to dry up secretions

and help reduce the "death rattle," which can be quite upsetting to the family.

Ethical issues

Like morphine used for controlling pain in palliative care, morphine used for controlling dyspnea prompts concern over whether the treatment hastens the patient's death. The general principles of treatment still apply: ie, the physician "may accept the risk that a patient may die during a particular treatment if more satisfactory treatment options are unavailable or undesirable, providing treatment has been discussed with the competent patient or guardian," as outlined in the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioural Research.¹⁴

However, because physicians have been taught that morphine is a respiratory depressant, its use in patients already dyspneic is counter-intuitive. And as dyspnea can be difficult to control, resulting in some degree of sedation, the effect of morphine is more evident than when used for pain control. It should be recalled, though, that the use of morphine for relief of terminal dyspnea does not necessarily result in deterioration of ventilatory function. Even if there are some adverse effects, the degree of distress to a patient with moderate to severe dyspnea is such that measures directed toward relief are easily justifiable. ■

Requests for reprints to: Dr David H.S. Hsu, The Seymour Medical Clinic, 1530 West 7th Ave, Vancouver, BC V6J 1S3

References

1. Fainsinger R, Miller MV, Bruera E, Hanson J, MacEachern T. Symptom control during the last week of life on a palliative care unit. *J Palliat Care* 1991;7(1):5-11.
2. Higginson I, McCarthy IA. Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? *J R Soc Med* 1989;82:264-7.
3. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. *Chest* 1986;89(2):234-6.
4. Twycross RG, Lack SA. *Therapeutics in terminal cancer*. London: Churchill Livingstone, 1990:123-36.
5. Saunders C. *The management of terminal malignant disease*. 2nd ed. London: Edward Arnold, 1984:113-9.

GROUP LIFE and DISABILITY INSURANCE

FOR MEMBERS
OF THE COLLEGE
OF FAMILY
PHYSICIANS
OF CANADA



Group coverage features:

- **Income Replacement Plan for Members** – provides up to \$3,500 per month when unable to work due to sickness or accident.
- **Income Replacement Plan for Employees of Members** – provides up to \$1,500 per month when unable to work due to sickness or accident.
- **Term Life Insurance Plans for Members and Employees of Members** – provides a choice of two plans through which benefits of up to \$300,000 are available.
- **Family Term Life Insurance Option** – provides up to \$100,000 in benefits for a spouse of a member or employee of a member, and \$5,000 for each dependent child.

For further information write to:

COLLEGE OF
FAMILY PHYSICIANS
OF CANADA

2630 Skymark Avenue,
Mississauga, Ontario,
Canada L4W 5A4

ONCE-A-DAY
ZESTRIL
LISINAPRIL

Tablets 5, 10 and 20 mg

Full Product Monograph Available on Request.

THERAPEUTIC CLASSIFICATION

Angiotensin Converting Enzyme Inhibitor

INDICATIONS AND CLINICAL USE

Essential and renovascular hypertension. May use with thiazide diuretics. Adjunctive therapy in congestive heart failure. **When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury or even death of the developing fetus. When pregnancy is detected ZESTRIL® should be discontinued as soon as possible.**

CONTRAINDICATIONS:

Hypersensitivity and history of angioneurotic edema.

WARNINGS

Angioedema: Discontinue and observe until swelling subsides. When tongue, glottis or larynx involved, administer adrenaline (0.5 mL 1:1000).

Hypotension: Patients with severe CHF, ischemic heart or cerebrovascular disease, should start therapy under close medical supervision and followed, when increasing dose of lisinopril and/or diuretic.

Neutropenia/Agranulocytosis: Monitor white blood cell counts. **Use in Pregnancy:** ACE inhibitors can cause fetal and neonatal morbidity and mortality when administered to pregnant women. Discontinue as soon as possible.

PRECAUTIONS

Impaired Renal or Liver Function: Use with caution.

Hemodialysis patients: Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes.

Cough: Consider as part of differential diagnosis.

Nursing Mothers: Use with caution.

Pediatric Use: Not recommended.

DRUG INTERACTIONS

Hypotension - Patients on Diuretic Therapy: Minimize by discontinuing diuretic prior to initiation of treatment with lisinopril and/or lowering initial dose of lisinopril. **Agents Increasing Serum Potassium:** Use potassium sparing diuretics with caution and monitor frequently.

Agents Causing Renin Release: Antihypertensive effect is augmented.

Agents Affecting Sympathetic Activity: Use with caution.

Indomethacin: May diminish antihypertensive efficacy.

Lithium Salts: Elimination may be reduced.

ADVERSE REACTIONS

Most frequent clinical adverse reactions (2633 hypertension and 636 CHF patients) were: dizziness 4.4%, headache 5.6%, asthenia/fatigue 2.7%, diarrhea 1.8% and cough 3.0%; 5.9% discontinued.

DOSAGE AND ADMINISTRATION

Administer in a single daily dose. Individualize dosage.

Essential Hypertension: 10 to 40 mg per day.

Diuretic Treated Patients: Discontinue diuretic two to three days before ZESTRIL®.

Dosage Adjustment in Renal Impairment (including patients on dialysis): Creatinine Clearance (31-70 mL/min) - 5.0 - 10.0 mg/day, (10-30 mL/min) - 2.5 - 5.0 mg/day, (<10 mL/min) - 2.5 mg; dosage and/or frequency of administration should be adjusted depending on the blood pressure response. Maximum of 40 mg daily. Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes.

Renovascular Hypertension: Starting dose of 2.5 or 5 mg.

Dosage in the Elderly: Make dosage adjustments with caution.

Congestive Heart Failure: Use in conjunction with digitalis and/or diuretic. Initiate under close medical supervision. Initial dose 2.5 mg per day.


AVAILABILITY

ZESTRIL 5 mg tablets are pale pink, round, biconvex, scored on one side and embossed with the number 5 inside a heart-shaped symbol on the other side. ZESTRIL 10 mg tablets are pale pink. ZESTRIL 20 mg are deep pink, round, biconvex, respectively embossed with the number 10 or 20 and "ZESTRIL" inside a heart-shaped symbol on one side and the ICI roundel on the other side. Bottles of 100. Calendar packs of 30.

References

1. Herpin D, Conte D. J. Hum Hyperten 1989;3:11-15.
2. Data on file, March 1991.

October 1992



ZENECA Pharma

Mississauga, Ontario L5N 5R7

A Member of the Zeneca Group
Un membre du groupe Zeneca

Further information available upon request

6. Coyle N, Adelhardt J, Foley KM, Portency RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. *J Pain Sympt Manage* 1990;5(2):83-93.
7. Ventafridda V, Ripamonti C, De Conno F, Tamburini MT, Cassileth BR. Symptom prevalence and control during cancer patients' last days of life. *J Palliat Care* 1990;6(3):7-11.
8. Altose DA. Assessment and management of breathlessness. *Chest* 1985;88(2 Suppl):77S-81S.
9. Wasserman K, Casaburi R. Dyspnea: physiological and pathophysiological mechanisms. *Annu Rev Med* 1988;39:503-15.
10. Billings JA. *Outpatient management of advanced cancer*. Philadelphia: JB Lippincott, 1985:83-7.
11. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. *BMJ* 1981;283:343-6.
12. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnea of terminal cancer patients. *J Pain Sympt Manage* 1990;5(6):341-4.
13. Henteleff PD. Dyspnea management: to take into the air my quiet breath. Selected Papers Palliative Care of Hospitalized Elderly. *Palliat Care* 1989;4:52-4.
14. Cohen MH, Anderson AJ, Krasnow SH, Spagnolo SV, Citron ML, Payne M, et al. Continuous intravenous infusion of morphine for severe dyspnea. *South Med J* 1991;84(2):229-34.
15. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. *N Engl J Med* 1981;305(27):1611-6.1

...